Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function

Exclusion Criteria

• •1. Taking a medication from a Prohibited Medication List.
• •2. Active pericarditis.
• •3. Presumed or documented history of vasculitis.
• •4. Uncontrolled hypertension (blood pressure \>180/110 mm Hg).
• •5. Dependency on renal dialysis.
• •6. Active internal bleeding or bleeding diathesis, surgery, trauma or gastrointestinal/genitourinary tract bleeding within 6 weeks prior to dosing.
• •7. Prior intracranial hemorrhage, hemorrhagic stroke, cerebrovascular accident (CVA) within 2 years or CVA with significant residual neurological deficit, intracranial neoplasm, arteriovenous malformation, intracranial aneurysm, or intracranial structural abnormality.
• •8. Thrombocytopenia (platelet count \<100 x 10³ µL) or history of thrombocytopenia following heparin, tirofiban, or eptifibatide administration.
• •9. Taking Over-the-Counter (OTC) vitamins and/or herbal supplements including garlic oil supplements, fish oil supplements, ginger supplements or onion extract pills within 14 days before dosing.
• •10. Participation in another clinical trial 30 days prior to participation in the current study.
• •11. Any other condition that in the opinion of the Investigator may compromise the safety or compliance of the subject or would preclude subject successfully completing the trial.
• •12. Female subjects who have a positive pregnancy test at Screening or Admission (Day 1), or who are breastfeeding.
• •13. Inability to comply with the protocol for the duration of the study.